ARA-290 10mg
$ 60.00 CAD
ARA-290 (Cibinetide) is an 11 amino acid peptide derived from the EPO molecule, but stripped of every effect on red blood cell production. It activates the innate repair receptor instead. This is the peptide with the strongest human clinical data for neuropathic pain and small fibre neuropathy, and it sits in a completely different class from the bioregulators.
ARA-290 10mg: The Innate Repair Receptor Peptide
Nerve pain is its own category of problem. It does not respond to the things that fix muscle and joint issues, it does not follow a normal healing timeline, and most compounds that help with inflammation do nothing for it at all.
ARA-290, also called Cibinetide, is an 11 amino acid peptide derived from the helix B region of the erythropoietin molecule. The key point is what was removed: ARA-290 has no effect on red blood cell production. It keeps only the tissue-protective signalling, which it delivers by activating the innate repair receptor.
What the Research Covers
- Small fibre neuropathy. ARA-290 has been through human clinical trials in sarcoidosis-related small fibre neuropathy, with measured improvement in corneal nerve fibre density.
- Neuropathic pain. Trials have measured pain scores and quality of life endpoints in neuropathy patients.
- Diabetic neuropathy. Research has examined metabolic control and nerve function in diabetic models.
- Inflammatory response. Innate repair receptor activation is anti-inflammatory without broad immune suppression.
- Tissue protection. Pre-clinical work covers kidney, cardiac and neural tissue under ischemic stress.
How It Differs From the Bioregulators
ARA-290 is not a Khavinson bioregulator and does not work the same way. The bioregulators are short peptides that act on gene expression in one specific tissue type. ARA-290 is a receptor agonist with a defined target and a much larger body of human clinical data behind it. If you are building a nerve protocol, ARA-290 is the evidence-backed centrepiece and Cortagen is the bioregulator that complements it.
Specs
- Compound: ARA-290 (Cibinetide)
- Structure: 11 amino acid EPO-derived peptide
- Mechanism: Innate repair receptor agonist
- Vial size: 10mg lyophilized powder
- Erythropoietic effect: None. Does not raise haematocrit.
- Storage: Refrigerate. Stable long-term unmixed.
Reconstitution and Storage
Ships as a sterile lyophilized powder. Reconstitute with bacteriostatic water. Once mixed, store refrigerated and use within 30 days. Keep the vial out of direct light and avoid repeated warming and cooling cycles.
For laboratory and research use only. Not for human consumption. Not approved by Health Canada for therapeutic use.
| Country | Canada, USA |
|---|---|
| Dosage | 10mg |
ARA-290: Dosage Protocol
- Clinical dose
- 4mg
- Lower dose
- 2mg
- How often
- Once a day
- Route
- Subcutaneous
- Run time
- 28 days
- Vials
- 12 at 4mg, 6 at 2mg daily
1. Mix it and draw it
Put 1mL of bac water into the 10mg vial. That makes 10mg per mL. On a 100-unit insulin pin, 10 units = 1mg. Units measure volume, not milligrams, so this only holds if you used 1mL of water.
| Protocol | Dose | Pull to | Shots per vial |
|---|---|---|---|
| Conservative | 2mg | 20 units | 5 |
| Clinical | 4mg | 40 units | 2 |
4mg drawn up.
- Swab the stopper. Run the water down the side of the glass, slowly.
- Swirl, do not shake. It should go clear.
- Pinch skin on the belly or thigh, inject, move to a new spot next time.
2. The schedule
Typical run shown below: 28 days. Time off after: not established.
One box = one week of the year. Red = on. 28 days per run.
3. Why this dose
4mg is the dose that was tested in people and worked. 2mg daily under the skin has not been tested: 1mg did very little and 4mg hit, so 2mg is somewhere in between and nobody knows where. Going above 4mg is pointless on current data, because 8mg did no better.
4. The evidence, ranked
Level 3 of 4. Four placebo-controlled human trials. Still not an approved drug.
Corneal nerve fibre area, square micrometres. Culver 2017. 4mg was the only dose to reach significance (P = 0.012).
| Study | What they did and found |
|---|---|
| Culver 2017, Invest Ophthalmol Vis SciPMID 28475703 | 64 patients, 28 days, 1 / 4 / 8mg daily against placebo. Corneal nerve fibre area went up significantly at 4mg only. Chart above. |
| Dahan 2013, Mol MedPMID 24136731 | 28 days of daily subQ shots. Better neuropathy symptoms, denser corneal nerve fibres, longer six minute walk. |
| Brines 2015, Mol MedPMID 25387363 | Type 2 diabetics with nerve pain, 4mg self-injected daily for 28 days. Pain scores improved, and HbA1c and lipids improved too. No safety flags. |
| Heij 2012, Mol MedPMID 23168581 | Pilot, 22 patients. 2mg IV three times a week for a month. Symptom score fell 11.5 points against 2.9 on placebo. |
| Brines 2008, PNASPMID 18676614 | The design paper. Shows the peptide protects tissue with no effect on red cell production. |
5. What you are injecting
11 amino acids in a chain. Formula C51H84N16O21, molecular weight 1257.3 g/mol.
EPO has two jobs. One is making red blood cells. The other is a repair signal sent to damaged tissue through a separate receptor. ARA-290 is an 11 amino acid copy of only the repair part. It triggers that receptor, calms inflammation and supports nerve fibre regrowth, and it leaves your haematocrit alone.
6. The gaps
Every trial was four weeks long and in patients with diagnosed neuropathy. Nothing on healthy users, nothing past 28 days, nothing on repeat runs.
7. Keeping it good
| Unmixed | Fridge, out of the light. Freezer if you are holding it for months. |
|---|---|
| Mixed | Fridge. Use inside 14 days. |
| Bin it if | It goes cloudy, has floaters, or sat warm for a day. |
Information on this tab comes from published studies and reported use. For laboratory and research use only. Not for human consumption. Not approved by Health Canada for therapeutic use.
Be the first to review “ARA-290 10mg”
You must be logged in to post a review.
Related products
Peptides
Peptides
Peptides
Peptides
Peptides
Fat Burners
Peptides
Peptides
Reviews
There are no reviews yet.